Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers.

Trial Profile

Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tenofovir dipivoxil fumarate (Primary) ; Lamivudine; Lopinavir/ritonavir; Zidovudine
  • Indications Hepatitis B; HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms TiP
  • Most Recent Events

    • 27 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 27 Jun 2012 Actual initiation date (1 May 2012) added as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top